![]() |
Scientific Newsletter |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
DATABASES Mutation Databases Tyrosinase |
Recent update from: 16.05.2010 |
||||||||||
Mutation Map
NCBI GenBank: 7299 - Gen Map (Built: GRCH37): 88911040-89028926 |
|||||||||||
Phenotype
|
Mutation
|
Basechange
|
Codon (Nucleotide)
|
Exon
|
Restriction site
|
HGMD / dbSNP
|
OMIM
|
Remarks
|
Reference |
||
| SNP | c.-5g>a | aggaa>agaaa | 0000 (c.-0005) | 5'UTR | |
|
dbSNP | ||||
| Polymorphism | c.-199c>a | tcgaa>tagaa | 0000 (c.-0199) | 5'UTR | |
V: 13 | (39)
(44)
|
||||
| Polymorphism | c.-259g>c | atggt>atcgt | 0000 (c.-0259) | 5'UTR | |
|
(41)
|
||||
| Polymorphism | c.-301c>t | aacct>aatct | 0000 (c.-0301) | 5'UTR | |
|
(39)
|
||||
| Polymorphism | c.-658del c | tgcag ctatc>tg_ag ctatc | 0000 (c.-0658) | 5'UTR | |
|
(28)
|
||||
| Polymorphism | c.-682ins g | tgaac aaatc>tgaag caaatc | 0000 (c.-0682) | 5'UTR | |
|
(28)
|
||||
| Polymorphism | c.-689ins c? | tatcc cacaa>tatcc ccaca a | 0000 (c.-0689) | 5'UTR | |
|
(28)
|
||||
| Polymorphism | c.-801ins gagagggaga | gaggg agagg>gaggg gagag ggaga agagg | 0000 (c.-0801) | 5'UTR | |
|
(28)
|
||||
| Polymorphism | (GA)n | 0000 (c.-0833) | 5'UTR | |
|
(33)
|
|||||
| Polymorphism | c.-961del g | gaggg ggaga>gaggg g_aga | 0000 (c.-0961) | 5'UTR | |
|
(28)
|
||||
| OCA | Deletion Exon 1 - 5 | 1-5 | |
|
Compound:
Patients: Netherlands |
(51)
|
|||||
| OCA1A | Deletion Exon 1 | 1 | |
|
Compound:
|
(8)
|
|||||
| OCA1 | Deletion Exon 1 - 5 | 1-5 | |
|
(54)
|
||||||
| OCA1 | Met 1 Val | ATG>GTG | 001 (c.0001) | 1 | V: 37 | Compound:
complete loss of activity |
(52)
|
||||
| AROA | Met 1 Val | ATG>GTG | 001 (c.0001) | 1 | V: 37 | Compound:
complete loss of activity |
(9)
(25)
(16)
(31)
(8)
(48)
(1)
|
||||
| OCA1A | Met 1 Thr | ATG>ACG | 001 (c.0002) | 1 |
|
|
(45) | ||||
| SNP | Leu 2 Leu | CTC>CTT | 002 (c.0006) | 1 | |
| dbSNP | ||||
| OCA1B | c.25delC | TGC CTG>TGC _TG | 009 (c.0025) | 1 | |
Compound:
|
(58)
(20)
|
||||
| OCA1A | Leu 9 Pro | CTG>CCG | 009 (c.0026) | 1 | |
|
(23)
|
||||
| OCA1A | c.48delC | TCC GCT>TC_ GCT | 018 (c.0048) | 1 | |
|
Compound:
|
(19)
|
|||
| OCA1A | c.53delG | GCT GGC>GCT G_C | 018 (c.0053) | 1 | |
Compound:
Patients: 1104 Argentinian |
(36)
(23)
|
||||
| OCA1A | His 19 Arg | CAT>CGA | 019 (c.0056) | 1 | |
|
Compound:
Patients: France |
(51)
(73)
|
|||
| OCA1A | His 19 Gln | CAT>CAA | 019 (c.0057) | 1 | |
Compound:
Patients: 608 Caucasian |
(36)
|
||||
| OCA1A | Pro 21 Ser | CCT>TCT | 021 (c.0061) | 1 | V: 23 | Compound:
|
(40)
(39)
(56)
(55)
(16)
(20)
(23)
(70)
|
||||
| OCA1A | Cys 24 Arg | TGT>CGT | 024 (c.0070) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1 | Cys 24 Tyr | TGT>TAT | 024 (c.0071) | 1 | |
|
Compound
Patients: Chinese |
(72)
(73)
|
|||
| OCA | Val 25 Phe | GTC>TTC | 025 (c.0073) | 1 | |
|
(46)
|
||||
| OCA1A | c.75insT | GTC TCC>GTT CTC C | 025 (c.0075) | 1 | |
|
Compound:
Patients: Israelites |
(23)
(46)
(52)
|
|||
| OCA1 | Thr 29 Pro (incorrect) | A>C | 029 (c.0096) | 1 | |
|
Position not present in reference sequence given by author.
|
(46)
|
|||
| OCA1A | Lys 33 Thr | AAG>ACG | 033 (c.0098) | 1 | |
|
Compound:
Patients: Turkey |
(51)
|
|||
| OCA1 | Cys 36 Tyr | TGT>TAT | 036 (c.0107) | 1 | |
(48)
|
|||||
| SNP | Pro 38 Thr | CCG>ACG | 038 (c.0112) | 1 | |
|
dbSNP | ||||
| SNP | Pro 38 Pro | CCG>CCA | 038 (c.0114) | 1 | |
|
dbSNP | ||||
| OCA1B | Trp 39 Arg | CGT>AGT | 039 (c.0115) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | Trp 39 ter | TGG>TAG | 039 (c.0116) | 1 | |
|
(23)
|
||||
| OCA1B | Trp 39 Cys | TGG>TGT | 039 (c.0117) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1B | Gly 41 Arg | GGG>AGG | 041 (c.0121) | 1 | |
|
Compound:
|
(23)
(73)
|
|||
| OCA1A | Asp 42 Asn | GAC>AAC | 042 (c.0124) | 1 | |
|
(6)
|
||||
| OCA1 | c.124delG | AGC GGG GAC>AGC GGG _AC | 042 (c.0124) | 1 | |
|
(20)
|
||||
| OCA1A | Asp 42 Gly | GAC>GGC | 042 (c.0125) | 1 | V: 19 | (40)
(39)
(56)
(55)
(21)
(23)
|
|||||
| OCA1 | Ser 44 Gly | AGT>GGT | 044 (c.0130) | 1 | |
|
(46)
|
||||
| OCA1 | Ser 44 Arg | AGT>CGT | 044 (c.0130) | 1 | |
|
(46)
|
||||
| SNP | Pro 45 Thr | CCC>ACC | 045 (c.0133) | 1 | |
|
(19)
|
||||
| OCA | Gly 47 Val | GGC>TGC | 047 (c.0139) | 1 | |
|
(46)
|
||||
| OCA1A | Gly 47 Asp | GGC>GAC | 047 (c.0140) | 1 | -HaeIII | V: 24 | Homozygous
Compound:
Patients: Israelites |
(35)
(3)
(55)
(37)
(10)
(23)
(52)
(46)
(20)
(53) |
|||
| OCA1A | Ser 50 ter | TCA>TGA | 050 (c.0149) | 1 | |
Homozygous
|
(10)
(74)
|
||||
| OCA1A | Arg 52 Ile | AGA>ATA | 052 (c.0155) | 1 | |
Compound:
Patients: 955 Korean |
(36)
|
||||
| AROA | Cys 55 Tyr | TGT>TAT | 055 (c.0164) | 1 | V: 20 | Compound:
|
(9)
(39)
(55)
(24)
(19)
(20)
|
||||
| OCA1A | Cys 55 Tyr | TGT>TAT | 055 (c.0165) | 1 | V: 20 | Disrupts disulfide bond or elminates copper binding
Compound:
|
(40)
(56)
(71)
(2)
(9)
(73)
|
||||
| SNP | Gln 56 His | CAG>CAT | 056 (c.0168) | 1 | |
|
dbSNP | ||||
| OCA1A | Arg 59 Gln | CGG>CAG | 059 (c.0312) | 1 | MspI-, BstNI+ | V: 10 | Homozygous
Nucleotide and amino acid numbering does not correspond to reference sequence |
(63)
|
|||
| SNP | Leu 60 Leu | CTG>TTG | 060 (c.0178) | 1 | |
|
dbSNP | ||||
| OCA1 | Gln 68 His | CAA>CAT | 068 (c.0204) | 1 | |
|
(46)
|
||||
| OCA1B | c.223delG | GTG GAT>GTG _AT | 075 (c.0223) | 1 | |
Compound:
Patients: 1309 Caucasian |
(36)
|
||||
| OCA1 | Asp 76 Glu | GAC>GAG | 076 (c.0228) | 1 | |
|
Compound:
|
(16)
|
|||
| OCA2 | Arg 77 Trp | CGG>TGG | 077 (c.0229) | 1 | |
Compound:
Patients: 70 |
(48)
(73)
|
||||
| OCA1B | Arg 77 Trp | CGG>TGG | 077 (c.0229) | 1 | |
Compound:
Patients: 70 Caucasian |
(36)
(58)
(23)
(20)
|
||||
| OCA1B | Arg 77 Gly | CGG>GGG | 077 (c.0229) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A/OCA2 | Arg 77 Gln | CGG>CAG | 077 (c.0230) | 1 | -MspI | V: 05 | Compound:
Patients: Japanese |
(40)
(39)
(55)
(63)
(47)
(48)
(28)
(73)
|
|||
| OCA1A/OCA2 | Arg 77 Gln | CGG>CAG | 077 (c.0230) | 1 | -MspI | V: 05 | Compound:
|
(48)
(3)
(31)
(71)
(46)
(23)
(64)
(72)
(49) |
|||
| OCA1A/B | Glu 78 ter | GAG>TAG | 078 (c.0232) | 1 | |
Compound:
|
(58)
(20)
|
||||
| OCA1A | c.232insGGG | CGG GAG>CGG GGG GAG | 078 (c.0232) | 1 | |
|
Compound
Patients: Chinese |
(71)
(72)
(73)
|
|||
| OCA1A/B | Ser 79 Pro | TCG>CCG | 079 (c.0235) | 1 | |
|
(23)
|
||||
| OCA1A/B | Ser 79 Leu | TCG>TTG | 079 (c.0236) | 1 | |
|
(46)
|
||||
| OCA1A | Trp 80 Arg | TGG>CGG | 080 (c.0238) | 1 | |
Compound:
|
(58)
(23)
(20)
|
||||
| OCA1A | Trp 80 ter | TGG>TGA | 080 (c.0240) | 1 | |
Compound:
Patients: 1117 Caucasian |
(36)
(3)
|
||||
| OCA1A/B | Pro 81 Ser | CCT>TCT | 081 (c.0241) | 1 | |
|
(23)
|
||||
| OCA1A | Pro 81 Leu | CCT>CTT | 081 (c.0242) | 1 | V: 02 | Homozygous
Compound:
Patients: France |
(12)
(39)
(48)
(56)
(51)
(20)
(23)
(49) |
||||
| OCA1B | Phe 84 Val | TTT>GTT | 084 (c.0255) | 1 | |
|
(20)
|
||||
| OCA1A | Tyr 85 ter | TAT>TAG | 085 (c.0255) | 1 | |
|
Compound:
|
(74)
(49) |
|||
| OCA1 | Cys 89 Arg | TGC>CGC | 089 (c.0265) | 1 | -BsrI | V: 11 | Resides in critical domain (C-G-N-C) conserved in TYR of different species and in TRP1 and TRP2
unprocessed and misfolded glycoform remains in ER possibly involved in C-C bonds |
(60)
(55)
(39)
(40)
(56)
|
|||
| SNP | Gln 90 Arg | CAG>CGG | 090 (c.0270) | 1 | |
|
dbSNP | ||||
| OCA1 | Cys 91 Ser | TGC>TCC | 091 (c.0272) | 1 | |
|
Compound:
Patients: Indian |
(31)
(6)
|
|||
| OCA1A | c.286insA | TTC ATG>TTC AAT G | 096 (c.0286) | 1 | V: 18 | (40)
(39)
(56)
(55)
(42)
(23)
(20)
|
|||||
| OCA1A | Gly 97 Arg | GGA>AGA | 097 (c.0289) | 1 | |
Compound:
Patients: 602 Caucasian |
(36)
(48)
|
||||
| OCA1A | Gly 97 Val | GGA>GTA | 097 (c.0290) | 1 | |
|
Homozygous
Compound:
Patients: Japanese |
(15)
|
|||
| OCA | Cys 100 Phe | TGT>TTT | 100 (c.0298) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | Gly 106 Arg | GGC>AGC | 106 (c.0316) | 1 | |
|
(23)
|
||||
| OCA | Gly 109 Arg | GGA>AGA | 109 (c.0325) | 1 | |
|
Possibly affects protein interactions and glycosylation
Compound:
|
(3)
|
|||
| OCA | c.338delCA | TGC ACA GAG>TGC A__ GAG | 113 (c.0338) | 1 | |
Compound:
|
(3)
(29)
(20)
|
||||
| OCA1A | c.344delGA | ACA GAG AGA CGA>ACA GAG A__ CGA | 115 (c.0344) | 1 | |
Homozygous
Compound:
|
(40)
(56)
(48)
(36)
(23)
(20)
|
||||
| OCA1A | Arg 116 ter | CGA>TGA | 116 (c.0346) | 1 | |
Homozygous
Compound:
Patients: 686 Caucasian Chinese |
(36)
(46)
(23)
(72)
(73)
|
||||
| OCA1B | Ile 123 Thr | TTT>GTT | 123 (c.0368) | 1 | |
|
(20)
|
||||
| OCA1A | Tyr 181 Cys | TAT>TGT | 123 (c.0542) | 1 | |
|
(20)
|
||||
| SNP | Asp 125 Tyr | GAT>TAT | 125 (c.0373) | 1 | |
|
dbSNP | ||||
| SNP | Asp 125 Gly | GAT>AAT | 125 (c.0374) | 2 | |
|
Compound:
|
(49) | |||
| SNP | Ala 128 Ala | GCC>GCA | 128 (c.0384) | 1 | |
|
dbSNP | ||||
| OCA1 | Lys 131 Glu | AAG>GAG | 131 (c.0391) | 1 | |
|
Compound:
Patients: Indian |
(31)
|
|||
| SNP | Lys 131 Lys | A>G | 131 (c.0393) | 1 | |
|
dbSNP | ||||
| SNP | Phe 134 Cys | TTT>TTG | 134 (c.0401) | 1 | |
|
dbSNP | ||||
| OCA1B | Lys 142 Asn | AAG>AAT | 142 (c.0426) | 1 | |
|
Compound:
Patients: Chinese |
(72)
|
|||
| OCA1B | Lys 142 Met | AAG>ATG | 142 (c.425) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | Tyr 149 Cys | TAT>TGT | 149 (c.0426) | 1 | |
|
(20)
|
||||
| OCA1 | Pro 152 Ser | CCC>TCC | 152 (c.0456) | 1 | |
Compound:
|
(10)
(56)
|
||||
| OCA1 | c.459insT | ATA GGG>ATT AGG G | 153 (c.0459) | 1 | |
Compound:
|
(48)
|
||||
| OCA1 | Thr 155 Ser | ACC>TCC | 155 (c.0463) | 1 | |
|
(46)
|
||||
| OCA1A | Ser 163 ter | TCA>TGA | 163 (c.0488) | 1 | |
|
Compound:
Patients: France |
(51)
|
|||
| OCA1A | c.505delGAC | AAC GAC ATC>AAC ___ ATC | 169 (c.050) | 1 | |
|
Compound:
Patients: England |
(51)
|
|||
| OCA1 | Phe 176 Ile | TTT>ATT | 176 (c.0526) | 1 | |
(35)
(39)
(40)
(56)
(38)
|
|||||
| OCA1 | Val 177 Phe | GTC>TTC | 177 (c.0529) | 1 | |
|
(46)
|
||||
| OCA1 | Trp 178 ter | TGG>TAG | 178 (c.0533) | 1 | +XbaI | V: 14 | (14)
(39)
(40)
(56)
(55)
|
||||
| OCA1 | Met 179 Leu | ATG>CTG | 179 (c.0535) | 1 | |
|
(46)
|
||||
| OCA1 | His 180 Asn | CAT>AAT | 180 (c.0538) | 1 | |
|
(46)
|
||||
| OCA2 | Met 185 Val | ATG>GTG | 185 (c.0553) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | c.572delG | CTT GGG GGA>CTT GGG G_A | 191 (c.0572) | 1 | V: 15 | (40)
(39)
(56)
(55)
(42)
(23)
(20)
|
|||||
| OCA1A | c.573delA | GGG GGA TCT>GGG GG_ TCT | 191 (c.0573) | 1 | |
|
Compound:
Patients: Turkey |
(51)
(23)
|
|||
| Polymorphism | Ser 192 Tyr | TCT>TAT | 192 (c.0575) | 1 | -DpnI, +MspI | |
V: 08 | Compound:
|
(40)
(39)
(56)
(55)
(48)
(12)
(49) (73)
|
||
| OCA1A | c.589delGA | TGG AGA GAC ATT>TGG AGA __ ATT | 197 (c.0589) | 1 | |
|
(23)
|
||||
| OCA1 | Asp 199 Asn | GAT>AAT | 199 (c.0595) | 1 | |
|
(46)
|
||||
| OCA1 | c.601delG | TTT GCC>TTT _C | 201 (c.0601) | 1 | |
|
(46)
|
||||
| OCA1 | Ala 201 Ser | GCC>TCC | 201 (c.0601) | 1 | |
|
(46)
|
||||
| OCA | Pro 205 Thr | CCA>ACA | 205 (c.0613) | 1 | |
|
Impairs copper-binding
|
(3)
(23)
(20)
|
|||
| OCA1 | Ala 206 Thr | GCT>ACT | 206 (c.0616) | 1 | -AluI | V: 21 | Compound:
|
(21)
(39)
(40)
(55)
(16)
|
|||
| OCA1 | Pro 209 Leu | CCT>CTT | 209 (c.0626) | 1 | |
|
(20)
|
||||
| OCA1A/B | Pro 209 Arg | CCT>CGT | 209 (c.0626) | 1 | |
|
(23)
|
||||
| OCA1A | His 211 Arg | CAT>CTT | 211 (c.0632) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | Arg 212 Thr | AGA>ACA | 212 (c.0635) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | Arg 212 Lys | AGA>AAA | 212 (c.0635) | 1 | |
|
(23)
|
||||
| OCA1 | Leu 216 Met | TTG>ATG | 216 (c.0646) | 1 | V: 36 | Compound:
|
(35)
(39)
(40)
(56)
|
||||
| OCA2, OCA1B | Arg 217 Trp | CGG>TGG | 217 (c.0649) | 1 | -AciI | V: 25 | Compound:
Patients: Israelites |
(70)
(40)
(39)
(56)
(48)
(20)
(48)
(39)
(55)
(52)
|
|||
| OCA | c.649delC | TTG CGG>TTG _GG | 217 (c.0649) | 1 | |
Compound:
Patients: Israelites |
(56)
(48)
(10)
(20)
(23)
(52)
|
||||
| OCA1 | Arg 217 Ser | CGG>TGG | 217 (c.0649) | 1 | |
|
(46)
|
||||
| OCA1A | Arg 217 Gly | CGG>GGG | 217 (c.0649) | 1 | -AciI |
|
|
Compound:
|
(58)
(57)
(20)
|
||
| OCA1 | Arg 217 Gln | CGG>CAG | 217 (c.0650) | 1 | -AciI |
|
|
Compound:
|
(39)
(40)
(56)
(48)
(38)
(20)
(19)
(23)
|
||
| OCA1 | Glu 219 ter | GAA>TAA | 219 (c.0655) | 1 | |
|
Compound:
Patients: France |
(51)
|
|||
| OCA1A | Glu 219 Lys | GAA>AAA | 219 (c.0655) | 1 | |
|
(6)
|
||||
| OCA1A | Asp 249 Gly | GAT>GGT | 219 (c.0746) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | Glu 221 Lys | GAA>AAA | 221 (c.0661) | 1 | |
|
(23)
|
||||
| OCA1 | Ile 222 Thr | ATC>ACC | 222 (c.0665) | 1 | |
|
Compound:
|
(16)
|
|||
| OCA | c.678delAGG | ACA GGA GAT>AC_ __A GAT | 226 (c.0678) | 1 | |
|
Compound:
|
(3)
(16)
|
|||
| OCA1A | Tyr 235 His | TAT>CAT | 235 (c.0703) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1A | Trp 236 Arg | TGG>CGG | 236 (c.0706) | 1 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| OCA1 | Trp 236 Ser | TGG>TCG | 236 (c.0707) | 1 |
|
|
Compound:
|
(48)
|
|||
| OCA1 | Trp 236 Leu | TGG>TTG | 236 (c.0707) | 1 | |
|
(46)
|
||||
| OCA1 | Trp 236 ter | TGG>TAG | 236 (c.0707) | 1 | V: 35 | Homozygous
|
(35)
(55)
(39)
(40)
(56)
|
||||
| OCA1 | Arg 239 Trp | GGG>TGG | 239 (c.0715) | 1 | |
|
Homozygous
|
(34)
(23)
(64)
(49) |
|||
| SNP | Arg 239 Gln | CGG>CAG | 239 (c.0716) | 1 | |
|
dbSNP | ||||
| OCA1 | Asp 240 Val | GAT>GTT | 240 (c.0719) | 1 | |
|
(46)
|
||||
| OCA1 | Lys 243 Thr | AAG>ACG | 243 (c.0728) | 1 | |
|
(46)
|
||||
| OCA1A | c.732delTG | AAG TGT GAC>AAG TG_ _AC | 245 (c.0732) | 1 | V: 17 | Compound:
Patients: Netherlands |
(39)
(55)
(48)
(8)
(51)
(20)
(49) |
||||
| OCA1A | Gly 253 Arg | GGA>AGA | 253 (c.0757) | 1 | -MnlI | |
Homozygous
Patients: Israelites |
(58)
(52)
|
|||
| OCA1A | Gly 253 Glu | GGA>GAA | 253 (c.0758) | 1 | |
|
Compound:
|
(23)
(73)
|
|||
| OCA1A | Gln 255 ter | CAG>TAG | 255 (c.0762) | 1 | |
|
(16)
|
||||
| OCA | His 256 Tyr | CAC>TAC | 256 (c.0766) | 1 | |
|
(3)
(46)
(72)
|
||||
| SNP | Pro 260 Leu | CCT>CTT | 260 (c.0779) | 1 | |
|
dbSNP | ||||
| SNP | Leu 263 Ile | CTC>ATC | 263 (c.0787) | 1 | |
|
dbSNP | ||||
| SNP | Ala 266 Thr | GCA>ACA | 266 (c.0796) | 1 | |
|
dbSNP | ||||
| OCA | Asp 271 Asn | G>A | 271 (c.0813) | 1 | |
|
Position not present in reference sequence given by author.
|
(46)
|
|||
| OCA1A | Trp 272 Arg | tcg>cgg | 272 (c.0814) | 1 | |
|
(74)
|
||||
| OCA1 | Trp 272 Cys | TGG>TGC | 272 (c.0816) | 1 |
|
|
Compound:
|
(48)
(18)
|
|||
| OA | Trp 272 Cys | TGG>TGC | 272 (c.0816) | 1 |
|
|
Compound:
|
(49) | |||
| OCA1A | IVS1-n - IVS2+m del | 274 (c.0820) | 2 | |
|
Compound:
Patients: France |
(51)
|
||||
| OCA1 | IVS1-3c>g | tacag>tagag | 274 (c.0820) | 2 | |
|
Abberant splicing
Compound:
Patients: Chinese |
(71)
(23)
(26)
(72)
(73)
|
|||
| OCA1 | IVS1-2del a | acag A | 274 (c.0820) | IVS 1 | |
|
(46)
|
||||
| OCA1A | IVS1-1gA>tG | cag AT>cat GT | 274 (c.0820) | IVS1 | |
|
Compound:
Patients: France |
(51)
|
|||
| OCA1 | Val 275 Phe | GTC>TTC | 275 (c.0823) | 2 |
|
V: 07 | Patients: France |
(11)
(39)
(55)
(51)
|
|||
| OCA1B | Val 275 Phe | GTC>TTC | 275 (c.0823) | 2 |
|
|
Compound:
|
(58)
(40)
(3)
(23)
(20)
|
|||
| OCA | Cys 276 Tyr | TGT>TAT | 276 (c.0827) | 2 | |
|
Compound:
|
(16)
|
|||
| OCA1 | Arg 278 ter | CGA>TGA | 278 (c.0832) | 2 |
|
|
Homozygous Compound:
Patients: Indian |
(68)
(10)
(55)
(31)
(73)
(27)
(64)
(23)
(15)
(4)
(6)
(72) |
|||
| SNP | Leu 279 Leu | TTG>CTG | 279 (c.0835) | 2 | |
|
dbSNP | ||||
| OCA1 | c.841delG | GAG GAG>GAG _AG | 281 (c.0841) | 2 |
|
|
Homozygous
|
(48)
|
|||
| OCA1 | c.842delA | GAG GAG>GAG G_G | 281 (c.0842) | 2 | |
|
(46)
|
||||
| SNP | Asn 283 Ile | AAC>ATG | 283 (c.0848) | 2 | |
|
dbSNP | ||||
| OCA1A | Cys 289 Gly | TGC>GGC | 287 (c.0875) | 2 | |
|
Patients: Chinese |
(71)
|
|||
| OCA1A | Leu 288 Ser | TTA>CTA | 288 (c.0872) | 2 | |
|
(41)
(40)
|
||||
| OCA1A | c.872delTT | CAG TCT TTA>CAG TCT __A | 288 (c.0872) | 2 | |
|
Reported as 861-862delTT
|
(71)
|
|||
| OCA1A | c.873delT | TCT TTA>TCT T_A | 288 (c.0873) | 2 |
|
|
(55)
(47)
(55)
|
||||
| OCA1A | Cys 289 Tyr | TGC>TAC | 289 (c.0846) | 2 | |
|
(23)
|
||||
| OCA1A | Cys 289 Arg | TGC>CGC | 289 (c.0875) | 2 |
|
|
Compound:
Patients: 207 Egyptian/Caucasian Chinese |
(36)
(48)
(71)
(46)
|
|||
| SNP | Thr 292 Met | ACG>ATG | 292 (c.0875) | 2 | |
|
dbSNP | ||||
| OCA1 | Glu 294 Gly | GAG>GGG | 294 (c.0880) | 2 |
|
|
Compound:
|
(48)
|
|||
| OCA1 | Glu 294 Lys | GAG>AAG | 294 (c.0880) | 2 |
|
|
Compound:
Patients: Israelites |
(10)
(48)
(3)
(23)
(55)
(20)
(52)
|
|||
| OCA1 | Gly 295 Arg | GGA>AGA | 295 (c.0883) | 2 | |
|
Compound:
Patients: Indian |
(31)
|
|||
| SNP | Leu 297 Leu | A>G | 297 (c.0891) | 2 | |
|
dbSNP | ||||
| OCA1A | Arg 299 Cys | CGT>TGT | 299 (c.0895) | 2 | |
|
Compound:
|
(16)
(73)
|
|||
| OCA1 | Arg 299 Ser | CGT>AGT | 299 (c.0895) | 2 | |
Homozygous
Compound:
Disrupts copper binding Patients: Chinese |
(58)
(71)
(39)
(55)
(23)
(26)
(20)
(72)
(73)
|
||||
| OCA1 | Arg 299 His | CGT>CAT | 299 (c.0896) | 2 | V: 26 | Homozygous Compound:
Disrupts copper binding Patients: Chinese Caucasian |
(47)
(20)
(72)
(74)
(23)
(73)
(70)
(40)
(10)
(56)
(47)
(71) |
||||
| OCA1A | c.911delATGA | AAC CAT GAC>AAC C__ __C | 304 (c.0911) | 2 | |
|
(23)
|
||||
| OA | Asp 305 Glu | GAC>GAA | 305 (c.0915) | 2 | |
|
Compound:
|
(16)
(23)
|
|||
| SNP | Arg 308 Thr | AGA>ACA | 308 (c.0923) | 2 | |
|
dbSNP | ||||
| OCA1A | c.929insC | AGA ACC CCA AGG>AGA ACC CCC AAG G | 310 (c.0929) | 2 | V: 27 | Homozygous
Compound:
Patients: Korean |
(40)
(39)
(55)
(71)
(47)
(65)
(70)
(64)
(15)
(72)
(73)
|
||||
| OCA1A | Leu 312 Val | CTC>GTC | 312 (c.0934) | 2 | |
Compound:
Patients: 523 |
(36)
|
||||
| OCA1A | c.937del8bp | CTC CCC TCT TCA GCT>CTC ___ ___ __A GCT | 313 (c.0937) | 2 | |
|
(62)
|
||||
| OCA1A | Pro 313 Arg | CCC>CGC | 313 (c.0938) | 2 | |
Compound:
Patients: 574 |
(36)
|
||||
| OCA1 | Val 318 Glu | GTA>GAA | 318 (c.0953) | 2 | |
|
(46)
|
||||
| SNP | Cys 321 Phe | TGC>TTC | 321 (c.0962) | 2 | |
|
(49) | ||||
| OCA1B | Thr 325 Ala | ACC>GCC | 325 (c.0973) | 2 | |
Compound:
|
(58)
(20)
|
||||
| OCA1A | Gln 326 ter | CAA>TAA | 326 (c.0976) | 2 | |
|
(6)
|
||||
| OCA1A | Tyr 327 Cys | TAT>TGT | 327 (c.0980) | 2 | |
|
(23)
|
||||
| OA | Glu 328 Lys | GAA>AAA | 328 (c.0982) | 2 | |
|
Compound:
|
(49) | |||
| OCA | Glu 328 Lys | GAA>AAA | 328 (c.0982) | 2 | |
|
Compound:
|
(49) | |||
| OCA1 | Glu 328 Gln | GAA>CAA | 328 (c.0982) | 2 | -HinfI | |
(68)
(56)
(55)
|
||||
| OCA1A | Ser 329 Pro | TCT>CCT | 329 (c.0985) | 2 | |
|
Compound:
|
(74)
(46)
(49) |
|||
| OCA1A | Met 332 Thr | ATG>GTG | 332 (c.0995) | 2 | |
|
(23)
(46)
|
||||
| OCA | Met 332 Ile | ATG>ATA | 332 (c.0996) | 2 | |
|
Homozygous
|
(16)
|
|||
| OCA1A | Ser 339 Gly | AGC>GGC | 339 (c.1015) | 2 | -AluI |
|
|
Compound:
|
(58)
(3)
|
||
| OCA1B | Phe 340 Leu | TTT>CTT | 340 (c.1018) | 2 |
|
|
Compound:
Patients: 608 Caucasian |
(36)
|
|||
| Polymorphism | Asn 342 Asn | AAT>AAC | 342 (c.1018) | 2 | |
|
(74)
|
||||
| OCA1 | Glu 345 Gly | GAA>GGÂ | 345 (c.1034) | 1 | |
|
(46)
|
||||
| OCA1A | Gly 346 ter | GGA>TGA | 346 (c.1036) | 2 | |
|
Homozygous
Compound:
Splice Site Mutation |
(41)
(23)
(49) |
|||
| OCA1a | IVS2>+60del 15bp | 346 (c.1036) | IVS2 | |
|
(74)
|
|||||
| OCA1A/B | IVS2+2t>g | G gtaa>G ggaa | 346 (c.1036) | IVS2 | |
|
(23)
|
||||
| OCA1A | Gly 346 Glu | GGA>GGG | 346 (c.1037) | 3 | |
|
Splice Site Mutation |
(41)
(74)
|
|||
| OCA1 | Gly 346 Val | CGA>CTA | 346 (c.1037) | 3 | |
|
Compound:
Patients: Indian |
(31)
|
|||
| OCA1B | IVS2-10deltt-7t>a | tttttaatgaa>ttt__aaagaa | 346 (c.1037) | IVS2 | |
|
Compound:
|
(47)
(15)
(30)
|
|||
| OCA1B | IVS2-7t>a | ttttgt>tttagt | 346 (c.1037) | IVS2 |
|
|
Homozygous
Compound:
Patients: Korean, Israelites |
(64)
(10)
(20)
(19)
(52)
(73) (48)
(55)
(54)
(16)
(23)
|
|||
| OCA1B | IVS2-1g>a | cagAT>caaAT | 346 (c.1037) | IVS2 |
|
|
Compound:
|
(58)
(19)
|
|||
| OCA1B | Ala 355 Pro | GCG>CCG | 355 (c.1063) | 3 | -AciI | |
Compound:
|
(58)
(56)
(55)
(48)
(3)
(20)
|
|||
| OCA1A | Ala 355 Glu | GCG>GAG | 355 (c.1064) | 3 | |
|
(41)
|
||||
| Polymorphism | Ala 355 Ala | GCG>GCA | 355 (c.1065) | 3 | |
|
(41)
(10)
|
||||
| OCA1A | Gln 359 ter | CAA>TAA | 359 (c.1075) | 3 |
|
|
Compound:
|
(58)
(46)
(20)
|
|||
| OCA1 | Gln 359 Leu | CAA>CTA | 359 (c.1076) | 3 | |
|
Compound:
|
(16)
(74)
|
|||
| OCA1 | Ser 360 Gly | AGC>GGC | 360 (c.1078) | 3 | |
|
(74)
|
||||
| OCA1A | Ser 361 Arg | AGC>CGC | 361 (c.1081) | 3 | |
|
(61)
|
||||
| OCA1 | His 363 Tyr | CAC>TAC | 363 (c.1087) | 3 | |
|
Reported as H363T
|
(46)
|
|||
| OCA1 | His 367 Tyr | CAC>TAC | 367 (c.1100) | 3 |
|
|
(1)
|
||||
| OCA1A | His 367 Arg | CAC>CGC | 367 (c.1100) | 3 | |
|
(40)
|
||||
| OCA1A | Tyr 369 Cys | TAA>TGT | 369 (c.1106) | 3 | |
|
(23)
|
||||
| OCA1 | Met 370 Thr | ATG>ACG | 370 (c.1109) | 3 | |
No Activity
Compound:
|
(1)
|
||||
| OCA | Met 370 Ile | ATG>ATA | 370 (c.1110) | 2 | |
|
Compound:
|
(49) | |||
| OCA1A | Asn 371 Tyr | AAT>TAT | 371 (c.1111) | 3 | |
Compound:
|
(48)
(39)
(61)
|
||||
| OCA1A | Asn 371 Thr | AAT>ACT | 371 (c.1112) | 3 | V: 28 | Compound:
|
(35)
(40)
(56)
(55)
(37)
(23)
|
||||
| OCA1A | Gly 372 Arg | GGA>AGA | 372 (c.1114) | 3 | |
|
(6)
|
||||
| OCA1A | Thr 373 Lys | ACA>AAA | 373 (c.1118) | 3 | V: 03 | Homozygous
Compound:
Patients: Israelites destroys glycosylation site at N371 retained in ER |
(23)
(59)
(46)
(19)
(20)
(52)
(58)
(40)
(48)
(10)
(56)
(3)
(17)
(1)
|
||||
| OA | Thr 373 Lys | ACA>AAA | 373 (c.1118) | 3 | |
V: 03 | Homozygous
Compound:
|
(16)
(49) |
|||
| OCA1A | Gln 376 ter | CAG>TAG | 376 (c.1126) | 3 | -MvaI | |
(56)
(55)
(68)
|
||||
| OCA | Val 377 Ala | GTA>GCA | 377 (c.1130) | 3 | |
|
Compound:
|
(49) | |||
| OCA1A | Gln 378 ter | CAG>TAG | 378 (c.1132) | 3 | -Csp6I | |
(40)
(39)
(55)
(38)
(20)
|
||||
| OCA1A | Gln 378 Lys | CAG>AAG | 378 (c.1132) | 3 | |
|
(46)
|
||||
| Polymorphism | Gly 379 Gly | GGA>GGT | 379 (c.1137) | 3 | |
|
(46)
|
||||
| OCA | Met 370 Ile | ATG>ATA | 380 (c.1110) | 3 | |
|
Compound:
|
(49) | |||
| OCA1B | Ser 380 Pro | TCT>CCT | 380 (c.1138) | 3 | -DpnI | |
Compound:
|
(58)
(55)
(20)
|
|||
| OCA | Asn 382 Lys | AAC>AAA | 382 (c.1146) | 3 |
|
V: 16 | Compound:
|
||||
| OCA1A | Asp 383 Asn | GAT>AAT | 383 (c.1147) | 3 | -DpnI |
|
V: 04 | Homozygous
Compound:
Patients: Caucasian |
(40)
(56)
(39)
(55)
(42)
(73)
(3)
(55)
(47)
(39)
(16)
(59)
(23)
(64)
(46)
(19)
(20)
(49) (73) |
||
| OCA1A | c.1161delT | TTC CTT CTT>TTC CT_ CTT | 388 (c.1161) | 3 | |
|
(40)
|
||||
| OCA2 | c.1164delT | CTT CAC>CT_ CAC | 388 (c.1164) | 3 |
|
V: 29 | (70)
(48)
(55)
(46)
(20)
|
||||
| SNP | His 389 His | CAC>CAT | 389 (c.1167) | 3 | |
|
dbSNP | ||||
| OCA1 | c.1167insT | CTT CAC CAT>CTT CAT CCA T | 390 (c.1167) | 3 | |
|
(46)
|
||||
| OCA1B | His 390 Asp | CAT>GAT | 390 (c.1168) | 3 | -NlaIII |
|
|
Compound:
|
(58)
(56)
(55)
(20)
(73)
|
||
| OCA1A | Ala 391 Glu | GCA>GGA | 391 (c.1172) | 3 | |
|
(23)
|
||||
| OCA1A | c.1176delT | GCA TTT GTT>GCA TT_ GTT | 392 (c.1176) | 3 | |
|
(23)
|
||||
| OCA1A | Val 393 Phe | GTT>TTT | 393 (c.1177) | 3 | |
|
(41)
(46)
|
||||
| OCA1 | c.1180delG | GTT GAC>GTT _AC | 394 (c.1180) | 3 | |
|
(46)
|
||||
| OCA1A | Ser 395 Arg | AG gttgg>CG gttgg | 395 (c.1183) | 4 | |
|
(20)
|
||||
| OCA1A | Ser 395 Asn | AG gttgg>AA gttgg | 395 (c.1184) | 4 |
|
|
Compound:
|
(58)
(20)
|
|||
| OCA1 | IVS3+3t>g | gttgg>gtggg | 395 (c.1184) | IVS 3 | |
|
(46)
|
||||
| OCA1 | del Exon 4-5 | 395 (c.1185) | 4 | |
|
(6)
|
|||||
| OCA1B | IVS3-1g>t | cag TA>cat TA | 395 (c.1185) | IVS3 | |
|
Compound:
Patients: Morocco |
(51)
|
|||
| OCA1 | Glu 398 Gly | GAG>GGG | 398 (c.1193) | 4 | |
|
Compound:
Patients: Indian |
(31)
|
|||
| OCA1A | Glu 398 Ala | GAG>GCG | 398 (c.1193) | 4 | |
|
(20)
|
||||
| OCA1 | Glu 398 Val | GAG>GTG | 398 (c.1194) | 4 | |
|
(46)
|
||||
| OCA1 | Trp 400 Leu | TGG>TTG | 400 (c.1199) | 4 | |
|
Disrupts copper binding Compound: Patients: Chinese |
(71)
(26)
(72)
(73)
|
|||
| OCA1B / OA | Trp 400 Cys | TGG>TGT | 400 (c.1200) | 4 | |
|
Compound:
Patients: France |
(51)
|
|||
| OCA1A | Arg 402 Gly | CGA>GGA | 402 (c.1204) | 4 | |
|
Compound:
|
(41)
(73)
|
|||
| OCA1A/B | Arg 402 ter | CGA>TGA | 402 (c.1204) | 4 | |
Homozygous
Compound:
|
(46)
(74)
(19)
(20)
(49) (73)
(10)
(56)
(48)
(55)
(23)
(52)
|
||||
| OCA1 | Arg 402 Leu | CGA>CTA | 402 (c.1205) | 4 | |
|
(46)
|
||||
| OA3, OCA1B disproven disproven | Arg 402 Gln | CGA>CAA | 402 (c.1205) | 4 | V: 09 | Temperature sensitive variant with permissive T at 32°C and non-permissive T at 37°C (27% activity of WT)
Compound:
Patients: France |
(51)
(9)
(1)
(39)
(55)
(43)
(49) (52)
(20)
(32)
(69)
(66)
| ||||
| Polymorphism | Arg 402 Gln | CGA>CAA | 402 (c.1205) | 4 | V: 09 | Temperature sensitive variant with permissive temperature at 32°C and non-permissive at 37°C
At non permissive temperature retained in the ER bound to calnexin Compound:
|
(40)
(56)
(55)
(69)
|
||||
| Polymorphism | Arg 402 Arg | CGA>CGC | 402 (c.1206) | 4 | |
|
(46)
|
||||
| OCA1A | c.1207delA | CGA AGG>CGA _GG | 402 (c.1207) | 4 | |
|
(74)
|
||||
| OCA1B/A | Arg 403 Ser | AGG>AGT | 403 (c.1209) | 4 |
|
V: 30 | Compound:
|
(46)
(46)
(40)
(39)
(56)
(55)
(48)
(46)
(20)
(70)
|
|||
| OCA1 | His 404 Asn | CAC>AAC | 404 (c.1210) | 4 | |
|
(46)
|
||||
| OCA1A | His 404 Pro | CAC>CCC | 404 (c.1211) | 4 |
|
|
Compound:
Patients: 853 Pakistani |
(36)
(73)
|
|||
| OCA1 | Arg 405 Leu | CGT>GGT | 405 (c.1214) | 4 | |
|
(46)
|
||||
| OCA1B | Pro 406 Leu | CCT>CTT | 406 (c.1217) | 4 |
|
V: 06 | Compound:
Patients: France |
(16)
(14)
(66)
(40)
(39)
(56)
(55)
(48)
(51)
(49) (73)
|
|||
| OA | Pro 406 Leu | CCT>CTT | 406 (c.1217) | 4 | |
V: 06 | Compound:
Patients: France |
(16)
(49) |
|||
| OCA1B | Pro 406 Leu | CCT>CTT | 406 (c.1217) | 4 | |
|
(14)
(66)
(23)
(5)
(46)
(20)
|
||||
| OCA1A | Glu 409 Asp | GAA>GAC | 409 (c.1227) | 4 | |
|
(46)
|
||||
| OCA1A | Pro 412 Ala | CCA>GCA | 412 (c.1234) | 4 | |
|
(23)
|
||||
| OCA1A | Glu 413 ter | GAA>TAA | 413 (c.1237) | 4 | |
|
(46)
|
||||
| OCA1 | Ala 416 Ser | GCA>TCA | 416 (c.1246) | 4 | |
|
(46)
|
||||
| OCA1 | Pro 417 His | CCC>CAC | 417 (c.1250) | 4 | |
|
(46)
|
||||
| OCA1A | Gln 408 His | CAA>CAC | 418 (c.1224) | 4 | |
|
(46)
|
||||
| OCA1A | Gly 419 Arg | GGA>AGA | 419 (c.1255) | 4 |
|
V: 22 | Homozygous Compound:
Patients: German Indian |
(40)
(39)
(56)
(55)
(48)
(31)
(46)
(21)
(68)
(23)
(6)
(20)
(73) |
|||
| OCA1TS | Arg 422 Trp | CGG>TGG | 422 (c.1264) | 4 | |
|
(23)
(49) |
||||
| OCA1TS | Arg 422 Gln | CGG>CAG | 422 (c.1265) | 4 |
|
V: 12 | Compound:
|
(67)
(13)
(46)
(20)
(67)
(13)
(73)
(40)
(39)
(56)
(55)
(48)
(2)
(16)
|
|||
| OCA1 | Ser 424 Phe | TCC>TTC | 424 (c.1271) | 4 | |
|
(46)
|
||||
| OCA1 | Met 426 Lys | ATG>AAG | 426 (c.1277) | 4 | |
|
(46)
|
||||
| OCA1A | Val 427 Gly | GTT>GGT | 427 (c.1280) | 4 | |
|
(46)
|
||||
| OCA1A | Pro 431 Thr | CCA>ACA | 431 (c.1291) | 4 | |
|
(55)
(23)
|
||||
| OCA1A | Pro 431 Leu | CCA>CTA | 431 (c.1292) | 4 |
|
|
(56)
(55)
(64)
(68)
(29)
|
||||
| OCA | Leu 432 Val | CTG>GTG | 432 (c.1294) | 4 | |
|
Compound:
|
(49) | |||
| OCA1B | Tyr 433 Cys | TAC>TGC | 433 (c.1298) | 4 | |
|
(74)
|
||||
| OCA1B | Tyr 433 ter | TAC>TAG | 433 (c.1299) | 4 | |
|
(50)
|
||||
| OCA1 | Arg 434 Ile | AGA>ATA | 434 (c.1302) | 4 | |
|
(46)
|
||||
| OCA1 | Asn 435 Asp | AAT>GAT | 435 (c.1303) | 4 | |
|
(46)
|
||||
| OCA1A | Gly 436 Arg | GGT>CGT | 436 (c.1306) | 4 | |
|
(23)
|
||||
| OCA1A | c.1314delCTTT | TTC TTT ATT>TT_ ___ ATT | 438 (c.1314) | 4 |
|
|
Compound:
|
(40)
(39)
(56)
(38)
|
|||
| OCA1A | c.1315delTTTinsC | TTC TTT ATT>TTC CAT T | 439 (c.1315) | 4 |
|
|
(2)
|
||||
| OCA1 | Phe 439 Val | TTT>GTT | 439 (c.1315) | 5 |
|
|
Compound:
|
(48)
|
|||
| OCA | Ser 442 Pro | TCC>CCC | 442 (c.1324) | 4 | |
|
Compound:
|
(49) | |||
| OCA1A | Asp 444 Gly | GAT>GGT | 444 (c.1331) | 4 | |
|
(46)
|
||||
| OCA1A | Gly 446 Ser | GGC>AGC | 446 (c.1336) | 4 |
|
V: 31 | Compound:
|
(20)
(23)
(70)
(58)
(55)
(40)
(39)
(48)
(3)
(16)
|
|||
| Polymorphism | Gly 446 Gly | GGC>GGG | 446 (c.1338) | 4 | |
|
(46)
|
||||
| OCA1A | Asp 448 Asn | GAC>AAC | 448 (c.1342) | 4 | |
|
(70)
(23)
(20)
(46)
(74)
|
||||
| OCA1A | Asp 448 Asn | GAC>AAC | 448 (c.1342) | 4 |
|
V: 32 | Homozygous
Compound:
|
(58)
(55)
(40)
(39)
(48)
|
|||
| OCA1A | Tyr 449 Cys | TAT>TGT | 449 (c.1346) | 4 | |
|
(23)
|
||||
| OCA1B | c.1348insGG | TAT AGC TAT>TAT GGA GCT AT | 450 (c.1348) | 4 | |
|
Compound
Patients: Chinese |
(72)
(73)
|
|||
| OCA1A | Gln 453 ter | CAA>TAA | 453 (c.1357) | 4 |
|
|
(40)
(39)
(38)
|
||||
| OCA1B | IVS4+4a>g | aaa gt>aga gt | 455 (c.1366) | IVS4 | |
|
(55)
(20)
|
||||
| OCA1B | IVS4+5a>g | aaa gt>aag gt | 455 (c.1366) | IVS4 |
|
|
Compound:
|
(58)
|
|||
| OCA1 | IVS4+1g>a | A G gta>A G ata | 455 (c.1366) | IVS4 | |
|
Compound:
Patients: France |
(51)
|
|||
| Polymorphism | Gly 456 Gly | ag AC>ac TC | 456 (c.1368) | 5 | |
|
Splice site mutation?
|
(46)
|
|||
| OCA1 | c.1379delTT | TCT TTT CAA>TCT T__ CAA | 460 (c.1379) | 5 | |
|
(62)
(6)
|
||||
| SNP | Phe 460 Ser | TTT>TCT | 460 (c.1379) | 5 | |
|
dbSNP | ||||
| OCA1 | c.1393insT | ATT AAG>ATTTAAG | 465 (c.1393) | 5 | |
|
Compound:
Patients: France |
(51)
|
|||
| OCA1 | Lys 465 ter | AAG>TAG | 465 (c.1393) | 5 | |
|
Compound:
Patients: France |
(51)
|
|||
| Polymorphism | Ala 471 Ala | GCG>GCA | 471 (c.1413) | 5 | |
|
(4)
(46)
|
||||
| OCA1 | c.1423del11bp | ATC TGG TCA TGG CTC>ATC ___ ___ ___ __C | 475 (c.1423) | 5 | |
|
(23)
|
||||
| OCA1A | Trp 475 ter | TGG>TGA | 475 (c.1425) | 5 | |
|
Compound:
Patients: Chinese carrier |
(72)
(73)
|
|||
| OCA1B | Ala 481 Glu | GCG>GAG | 481 (c.1442) | 5 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
| Polymorphism | Ala 482 Ala | GCG>GCC | 482 (c.1446) | 5 | |
|
(46)
|
||||
| OCA1A | c.1468insT | ACT GCC>ACT TGC C | 490 (c.1468) | 5 | V: 33 | Compound:
Patients: England |
(40)
(55)
(39)
(56)
(51)
(16)
|
||||
| OCA1A | c.1468insT | ACT GCC>ACT TGC C | 490 (c.1468) | 5 | V: 33 | Compound:
Patients: England |
(19)
(20)
(46)
(23)
(22)
(7)
|
||||
| OCA1 | Ala 490 Gly | GCC>GGC | 490 (c.1469) | 5 | |
|
Homozygous:
Compound:
|
(16)
(23)
|
|||
| OCA1A | c.1502insC | TGT CGT>TGT CCG T | 501 (c.1502) | 5 |
|
V: 34 | (40)
(39)
(56)
(55)
(14)
(46)
|
||||
| OCA1B | Gln 506 ter | CAG>TAG | 506 (c.1516) | 5 | |
|
Compound:
Patients: Chinese |
(73)
|
|||
References:
|
|||||||||||